Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Diagnostic & Testing Substances Manufacturers
- Sub-Industry: N/A
- Symbol: NASDAQ:CEMI
- CUSIP: N/A
- Web: www.chembio.com
Capitalization:- Market Cap: $74.47 million
- Outstanding Shares: 12,309,000
Average Prices:- 50 Day Moving Avg: $6.13
- 200 Day Moving Avg: $6.10
- 52 Week Range: $5.05 - $7.45
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -30.25
- P/E Growth: -0.47
Sales & Book Value:- Annual Revenue: $18.44 million
- Price / Sales: 4.04
- Book Value: $1.25 per share
- Price / Book: 4.84
Profitability:- EBIDTA: ($7,170,000.00)
- Net Margins: -51.99%
- Return on Equity: -48.79%
- Return on Assets: -40.54%
Debt:- Current Ratio: 3.66%
- Quick Ratio: 2.37%
Misc:- Average Volume: 22,577 shs.
- Beta: 1.23
- Short Ratio: 3.88
Frequently Asked Questions for Chembio Diagnostics (NASDAQ:CEMI)
What is Chembio Diagnostics' stock symbol?
Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."
How were Chembio Diagnostics' earnings last quarter?
Chembio Diagnostics, Inc. (NASDAQ:CEMI) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.02. The company had revenue of $2.89 million for the quarter, compared to analyst estimates of $4.96 million. Chembio Diagnostics had a negative return on equity of 48.79% and a negative net margin of 51.99%. View Chembio Diagnostics' Earnings History.
Where is Chembio Diagnostics' stock going? Where will Chembio Diagnostics' stock price be in 2017?
1 brokerages have issued 1 year price targets for Chembio Diagnostics' stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Chembio Diagnostics' stock price to reach $9.00 in the next year. View Analyst Ratings for Chembio Diagnostics.
Who are some of Chembio Diagnostics' key competitors?
Some companies that are related to Chembio Diagnostics include XOMA Corporation (XOMA), Dimension Therapeutics (DMTX), XBiotech (XBIT), Adverum Biotechnologies (ADVM), Trevena (TRVN), Quorum Health Corporation (QHC), Oramed Pharmaceuticals (ORMP), Peregrine Pharmaceuticals (PPHM), Invuity (IVTY), GTx (GTXI), Neovasc (NVCN), Regulus Therapeutics (RGLS), T2 Biosystems (TTOO), Axsome Therapeutics (AXSM), Nuvectra Corporation (NVTR), Cidara Therapeutics (CDTX), SeaSpine Holdings Corporation (SPNE) and Marinus Pharmaceuticals (MRNS).
Who are Chembio Diagnostics' key executives?
Chembio Diagnostics' management team includes the folowing people:
- Sharon Klugewicz, Acting Chief Executive Officer
- Richard J. Larkin, Chief Financial Officer
- Javan Esfandiari, Chief Science and Technology Officer
- Tom Ippolito, Vice President - Regulatory Affairs, Quality Assurance and Quality Control
- Paul Lambotte Ph.D., Vice President - Product Development
- Michael K. Steele, Vice President - Business Development, Sales and Marketing
- Katherine L. Davis, Non-Executive Independent Chairman of the Board
- Gail S. Page, Director
- Peter T. Kissinger Ph.D., Independent Director
- Gary Meller M.D., Independent Director
Who owns Chembio Diagnostics stock?
Chembio Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include ARS Investment Partners LLC (5.46%), Vanguard Group Inc. (2.88%), Wells Fargo & Company MN (0.60%), Perkins Capital Management Inc. (0.38%), New Jersey Better Educational Savings Trust (0.26%) and Goldman Sachs Group Inc. (0.20%). Company insiders that own Chembio Diagnostics stock include Javan Esfandiari, Norman H Pessin and Sharon W Klugewicz. View Institutional Ownership Trends for Chembio Diagnostics.
Who sold Chembio Diagnostics stock? Who is selling Chembio Diagnostics stock?
Who bought Chembio Diagnostics stock? Who is buying Chembio Diagnostics stock?
Chembio Diagnostics' stock was purchased by a variety of institutional investors in the last quarter, including ARS Investment Partners LLC, Wells Fargo & Company MN, Goldman Sachs Group Inc. and Royce & Associates LP. View Insider Buying and Selling for Chembio Diagnostics.
How do I buy Chembio Diagnostics stock?
Shares of Chembio Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chembio Diagnostics' stock price today?
One share of Chembio Diagnostics stock can currently be purchased for approximately $6.05.
MarketBeat Community Rating for Chembio Diagnostics (NASDAQ CEMI)MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Chembio Diagnostics (NASDAQ:CEMI) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $9.00 (48.76% upside) |
Analysts' Ratings History for Chembio Diagnostics (NASDAQ:CEMI)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/11/2016 | Benchmark Co. | Set Price Target | Buy | $9.00 | N/A |  |
(Data available from 9/25/2015 forward)
Earnings History for Chembio Diagnostics (NASDAQ:CEMI)Earnings History by Quarter for Chembio Diagnostics (NASDAQ CEMI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/9/2017 | Q2 2017 | ($0.17) | ($0.18) | $4.96 million | $2.89 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.20) | ($0.13) | $4.88 million | $5.43 million | View | Listen | |
| 3/7/2017 | Q4 2016 | ($0.15) | ($0.21) | $4.44 million | $4.26 million | View | Listen | |
| 11/10/2016 | Q3 2016 | ($0.17) | ($0.19) | $3.76 million | $3.75 million | View | N/A | |
| 8/11/2016 | Q2 | ($0.11) | ($0.86) | $6.72 million | $3.27 million | View | Listen | |
| 5/12/2016 | Q1 | ($0.09) | ($0.03) | $4.83 million | $6.60 million | View | Listen | |
| 3/8/2016 | Q4 | ($0.09) | ($0.07) | $6.56 million | $4.42 million | View | N/A | |
| 11/12/2015 | Q3 | ($0.09) | ($0.05) | $6.77 million | $6.89 million | View | Listen | |
| 8/6/2015 | Q2 | ($0.03) | ($0.07) | $7.53 million | $6.72 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.08) | ($0.07) | $5.20 million | $6.20 million | View | N/A | |
| 3/5/2015 | Q414 | ($0.04) | ($0.05) | $7.10 million | $7.10 million | View | N/A | |
| 11/6/2014 | Q3 2014 | ($0.03) | ($0.03) | $7.71 million | $7.31 million | View | N/A | |
| 8/7/2014 | Q2 | ($0.02) | ($0.02) | $6.25 million | $7.42 million | View | N/A | |
| 5/8/2014 | Q1 2014 | ($0.02) | ($0.02) | $6.87 million | $5.81 million | View | N/A | |
| 3/6/2014 | Q413 | $0.04 | ($0.03) | $7.05 million | $7.86 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.04) | ($0.03) | $5.56 million | $5.39 million | View | N/A | |
| 5/9/2013 | Q1 2013 | $0.06 | $0.04 | | | View | N/A | |
| 11/13/2012 | Q312 | $0.04 | ($0.04) | $6.11 million | $5.01 million | View | N/A | |
| 8/9/2012 | | $0.05 | $0.04 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Chembio Diagnostics (NASDAQ:CEMI)2017 EPS Consensus Estimate: ($0.55)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.19) | ($0.19) | ($0.19) |
| Q2 2017 | 2 | ($0.17) | ($0.15) | ($0.16) |
| Q3 2017 | 2 | ($0.11) | ($0.09) | ($0.10) |
| Q4 2017 | 1 | ($0.10) | ($0.10) | ($0.10) |
(Data provided by Zacks Investment Research)
Dividend History for Chembio Diagnostics (NASDAQ:CEMI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Chembio Diagnostics (NASDAQ:CEMI)Insider Ownership Percentage: 5.56%
Institutional Ownership Percentage: 30.74%
Insider Trades by Quarter for Chembio Diagnostics (NASDAQ:CEMI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/28/2017 | Norman H Pessin | Insider | Buy | 36,250 | $5.48 | $198,650.00 | |
| 6/15/2016 | Sharon W Klugewicz | COO | Sell | 3,000 | $8.40 | $25,200.00 | |
| 6/1/2016 | Javan Esfandiari | Insider | Sell | 25,000 | $8.58 | $214,500.00 | |
| 5/29/2015 | Javan Esfandiari | Insider | Sell | 20,000 | $4.50 | $90,000.00 | |
| 11/19/2014 | Peter Kissinger | Director | Buy | 1,800 | $4.31 | $7,758.00 | |
| 2/26/2014 | Sharon W Klugewicz | COO | Buy | 10,000 | $3.50 | $35,000.00 | |
| 12/6/2013 | Javan Esfandiari | SVP | Sell | 10,000 | $3.40 | $34,000.00 | |
| 11/11/2013 | Lawrence A Siebert | Major Shareholder | Sell | 30,000 | $3.63 | $108,900.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Chembio Diagnostics (NASDAQ:CEMI)
Latest Headlines for Chembio Diagnostics (NASDAQ:CEMI)
| Source: |
|
| Date | Headline |
|---|
 | BRIEF-Chembio Diagnostics says CFO Richard Larkin to retire by Dec 31
www.reuters.com - August 17 at 11:24 PM |
 | Chembio Diagnostics (CEMI) CFO to Retire
www.streetinsider.com - August 17 at 6:23 PM |
 | Chembio Diagnostics Announces Retirement of Chief Financial Officer
finance.yahoo.com - August 17 at 6:23 PM |
 | Chembio Diagnostics' (CEMI) CEO John Sperzel on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 11 at 5:29 PM |
 | Chembio Diagnostics, Inc. (CEMI) Posts Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - August 10 at 9:28 PM |
| Edited Transcript of CEMI earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 6:15 PM |
| Chembio Diagnostics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 5:16 PM |
| Investor Network Invites You to the Chembio 2017 Second Quarter Earnings Conference Call and Webcast Live on Wednesday, August 9, 2017
finance.yahoo.com - August 8 at 4:49 PM |
| Chembio to Host Conference Call to Discuss Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 6:35 PM |
| Gail S. Page Joins Chembio Diagnostics Board of Directors
finance.yahoo.com - July 6 at 6:19 PM |
| Chembio Diagnostics (CEMI) DPP Zika System Plus DPP Micro Reader Granted Approval by Brazilian Health Regulatory Agency
www.streetinsider.com - July 5 at 10:53 PM |
| Chembio’s DPP® Zika System Including the DPP® Micro Reader Approved by Brazil’s Health Regulatory Agency
finance.yahoo.com - July 5 at 5:49 PM |
| Chembio Diagnostics, Inc. (CEMI) Insider Purchases $198,650.00 in Stock
www.americanbankingnews.com - June 29 at 8:11 PM |
| Chembio Diagnostics (CEMI) Diagnostics Announces $21.2M At-The-Market Program
www.streetinsider.com - June 27 at 9:31 PM |
| Chembio Diagnostics Announces At-The-Market Program
finance.yahoo.com - June 27 at 9:31 PM |
| ETFs with exposure to Chembio Diagnostics, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 4:59 PM |
| Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 5:01 PM |
| ValuEngine Upgrades Chembio Diagnostics Inc (CEMI) to "Sell"
www.americanbankingnews.com - June 5 at 10:34 PM |
| Q2 2017 EPS Estimates for Chembio Diagnostics Inc Cut by Analyst (CEMI)
www.americanbankingnews.com - May 22 at 7:18 AM |
| CEMI New Strategy Paying Dividends As Product Sales Bounce Back
finance.yahoo.com - May 18 at 4:10 PM |
| Q2 2017 Earnings Estimate for Chembio Diagnostics Inc (CEMI) Issued By Craig Hallum
www.americanbankingnews.com - May 15 at 7:58 AM |
| Chembio Diagnostics Inc (CEMI) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 2:20 PM |
| Chembio Diagnostics' (CEMI) CEO John Sperzel on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 4:24 PM |
| Edited Transcript of CEMI earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 8:30 AM |
| Investor Network: CHEMBIO DIAGNOSTICS, INC. to Host Earnings Call
finance.yahoo.com - May 9 at 4:12 PM |
| Chembio Diagnostics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 4:12 PM |
| Investor Network Invites You to the Chembio 2017 First Quarter Earnings Conference Call and Webcast Live on Tuesday, May 9, 2017
finance.yahoo.com - May 8 at 4:09 PM |
| Positive News Coverage Very Likely to Impact Chembio Diagnostics (CEMI) Stock Price
www.americanbankingnews.com - May 3 at 10:12 PM |
| Chembio Secures $5.8 Million Bio-Manguinhos Order to Supply Components for Production of DPP® HIV 1/2 Assay in Brazil
finance.yahoo.com - May 3 at 8:54 AM |
| Chembio to Host Conference Call to Discuss First Quarter 2017 Financial Results
finance.yahoo.com - May 2 at 7:26 PM |
| Somewhat Favorable News Coverage Likely to Impact Chembio Diagnostics (CEMI) Stock Price
www.americanbankingnews.com - April 27 at 8:14 PM |
| Chembio Diagnostics (CEMI) Given Daily Media Impact Rating of 0.33
www.americanbankingnews.com - April 15 at 11:21 AM |
| Chembio and FIND Collaborate to Develop Point-of-Care Multiplex Test for Acute Febrile Illnesses in Asia Pacific
finance.yahoo.com - April 7 at 8:56 AM |
| ETFs with exposure to Chembio Diagnostics, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 8:56 AM |
| CHEMBIO DIAGNOSTICS, INC. Financials
finance.yahoo.com - March 11 at 4:11 PM |
| CEMI: Surprise Rebound In Lateral Flow, Expect DPP Strong Showing In 2017
finance.yahoo.com - March 10 at 5:14 PM |
| CHEMBIO DIAGNOSTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 7 at 4:16 PM |
| Chembio Diagnostics Reports 2016 Financial Results
finance.yahoo.com - March 7 at 4:16 PM |
| The Top 200 Developers of In-Vitro Diagnostics Tests for Cancer & Infectious Diseases
finance.yahoo.com - March 7 at 12:28 PM |
| Q4 2016 Chembio Diagnostics Inc Earnings Release - After Market Close
biz.yahoo.com - March 7 at 12:28 PM |
| Investor Network Invites You to the Chembio 2016 Year-End Earnings Conference Call and Webcast Live on Tuesday, March 7, 2017
finance.yahoo.com - March 6 at 4:09 PM |
| CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - February 28 at 4:27 PM |
| Chembio to Host Conference Call to Discuss 2016 Financial Results
finance.yahoo.com - February 27 at 2:26 PM |
| Worldwide Top 600 In-Vitro Diagnostics Companies 2017 - Research and Markets
finance.yahoo.com - February 3 at 9:29 PM |
| Form 8-K CHEMBIO DIAGNOSTICS, For: Jan 27
www.streetinsider.com - January 29 at 2:25 AM |
| Chembio Appoints Sales Executives in Latin America, Africa, Asia Pacific
finance.yahoo.com - January 26 at 5:04 PM |
 | ADHD Doesn't MEASURE Up, JAZZ Abuzz, NBIX Slips On Failed Study
www.rttnews.com - January 18 at 3:03 AM |
| Chembio’s DPP® HIV-Syphilis Assay Receives CE Mark for Simultaneous Point-of-Care Detection of HIV and Syphilis
finance.yahoo.com - January 17 at 9:07 AM |
| Chembio Completes Acquisition of Malaysia-based RVR Diagnostics
finance.yahoo.com - January 10 at 4:55 PM |
| The Top 200 Point-Of-Care Diagnostics Companies Worldwide
finance.yahoo.com - December 16 at 9:43 PM |
Chembio Diagnostics (CEMI) Chart for Monday, September, 25, 2017
